Maria Sklodowska-Curie National Research Institute of Oncology

Nemtabrutinib Shows Promise in Relapsed/Refractory Follicular Lymphoma

6 months ago

• Nemtabrutinib demonstrates encouraging efficacy in patients with relapsed or refractory follicular lymphoma, according to findings from the BELLWAVE-003 phase 2 trial. • The study, presented at the 2024 ASH Annual Meeting, highlights the potential of nemtabrutinib as a treatment option for this patient population. • Safety data from the trial indicate a manageable toxicity profile, supporting the continued investigation of nemtabrutinib in follicular lymphoma. • Further research is warranted to confirm these findings and explore the optimal use of nemtabrutinib in the treatment landscape.

Immutep's Efti Shows Promise in Neoadjuvant Soft Tissue Sarcoma Treatment

8 months ago

• Immutep's EFTISARC-NEO Phase II trial evaluates eftilagimod alpha (efti) with radiotherapy and pembrolizumab in soft tissue sarcoma patients. • Initial data from the trial shows encouraging results, with deep responses observed in the majority of the first six patients. • The EFTISARC-NEO trial is the first to assess efti in a neoadjuvant setting, allowing for assessment of its impact on the tumor microenvironment. • The trial is being conducted at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw and is funded by a Polish government grant.